BEAM

20.8600.38%
GC

Giuseppe Ciaramella

President

Dr. Giuseppe Ciaramella, also known as Pino, Ph.D., serves as Director at Dewpoint Therapeutics, Inc. July 2020. Dr. Ciaramella had been Chief Scientific Officer at Beam Therapeutics Inc. since February 2018 and serves as its President since January, 2020. Since March 2022, Dr. Ciaramella is Co-Founder of Orbital Therapeutics Inc. and was its Chief Executive Officer & Director until September 2024 and is its Scientific & Strategic Advisor from September 2024. He has served as the interim Chief Executive Officer and as a member of the board of directors of Orbital Therapeutics, Incorporated. Dr. Ciaramella serves as Chief Scientific Officer at Valera LLC. Dr. Ciaramella has been the Chief Scientific Officer of Infectious Disease at Moderna since October 2014. He served as Vice President and Head of immunology and biotherapeutics at Moderna. Dr. Ciaramella has nearly two decades of global industry experience at AstraZeneca, Boeringher Ingelheim, Pfizer and Merck focused on the discovery and development of small molecule and biological clinical candidates, with a particular focus on antivirals and biotherapeutics. Dr. Ciaramella has drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck and has held several leadership roles, with a particular focus in the fields of antivirals, immunology and biotherapeutics. Prior to joining Moderna, he led the small molecule Antiviral Strategy at AstraZeneca. At Boehringer Ingelheim, he served as Vice President and Head of Collaborative Research where he had responsibility for external R&D and was a member of the WW Research Leadership Team. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer in the UK where he held several Discovery leadership positions, including head of Biotherapeutics, head of Antiviral and head of Lead Discovery. During his career, he has contributed to several clinical candidates, both small molecule and biologics and to the anti-HIV drug Maraviroc (Selzentry TM), which won the USA Prix Galien for Best Pharmaceutical in 2008. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, a pharmaceutical company, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer Inc., a biopharmaceutical company, in the United Kingdom where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. He is a Fellow of the Royal Society of Chemistry (UK) and he is a member of the Infectious Diseases Society of America (IDSA). Dr. Ciaramella holds a PhD in Biochemistry and Molecular Biology from University College London in 1994 and BSc, Biochemistry from University College London in 1990.

Positions